Filing summary
Entity note: The supplied filing identifies the registrant as TRxADE HEALTH, Inc. (Nasdaq: MEDS), not Scienture Holdings, Inc. The summary below reflects the filing text. It is the annual report for the fiscal year ended December 31, 2023, filed April 22, 2024; it does not provide standalone fourth-quarter results.
Business context and reporting period
In 2023, TRxADE operated a pharmaceutical marketplace, a pharmaceutical wholesale/logistics business (Integra), and acquired food-technology company Superlatus and food business The Urgent Company (TUC). It also sold Community Specialty Pharmacy and Alliance Pharma Solutions (APS), which are reported as discontinued operations. After year-end, the company sold substantially all marketplace assets and divested Superlatus, marking substantial changes to its business and asset base.
Financial performance and position
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $8.27 million | $10.25 million |
| Gross profit / margin | $2.60 million / 31.4% | $5.52 million / 53.8% |
| Operating loss | $7.26 million | $2.92 million |
| Net loss from continuing operations | $13.72 million | $2.40 million |
| Net loss including discontinued operations | $17.84 million | $3.91 million |
| Cash used in operating activities | $2.07 million | $1.56 million |
| Cash at year-end | $151,908 | $1.09 million |
| Working capital | $(8.80) million | $(53,668) |
Revenue declined 19.3%. Marketplace transaction-fee revenue rose 16% to $6.20 million, while Integra revenue fell 71% to $1.36 million. Lower gross margin reflected increased food-business inventory costs and write-downs. The company recorded a $5.13 million goodwill impairment tied to Superlatus, $1.19 million of interest expense, and a $148,420 loss from the change in warrant fair value; the prior year included an $825,544 warrant fair-value gain.
At December 31, 2023, total assets were $12.53 million, total liabilities $11.99 million, and stockholders’ equity $542,353. Current liabilities were $11.56 million, including $6.53 million of current notes payable and $1.25 million of contingent funding liabilities. Long-term notes payable were $25,000. The filing reports no material unused sources of liquidity and no off-balance-sheet arrangements.
Cash from financing activities was $1.41 million, including $2.18 million of proceeds from sales of future receivables, partly offset by repayments. The receivables funding carried an approximately 31% effective interest rate. Cash interest paid was $733,694.
Material changes, outlook and unusual items
- Subsequent asset sale: On February 16, 2024, the company sold substantially all TRxADE marketplace assets to Micro Merchant Systems for $22.5 million in cash, subject to customary adjustments. An additional $7.5 million may be payable if specified collections reach at least $1.6 million within four months of closing.
- Other post-year-end transactions: On March 5, 2024, the company sold all Superlatus stock for $1. On March 6, it declared an $8-per-share special dividend funded from a portion of marketplace-sale proceeds. The filing also describes a proposed investment of up to $5 million in Lafayette Energy, a company led by a TRxADE director; the second tranche is conditional.
- Liquidity and going concern: Management says additional funding is needed to continue operations at current levels and meet public-company costs. The company had a $8.80 million working-capital deficit, $151,908 in cash and an accumulated deficit of $33.25 million at year-end. Management and the auditor state that these conditions raise substantial doubt about the company’s ability to continue as a going concern. Potential funding through debt or equity is not assured and could dilute shareholders.
- 2024 plans: Management expects to focus on Integra, pursue strategic transactions and consider acquisitions. It estimates approximately $4.8 million of 2024 general and administrative and working-capital expenses. The filing does not provide revenue or earnings guidance.
- Controls and reporting: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end, citing a non-integrated reporting system, extensive manual processes, inadequate segregation of duties and insufficient technical accounting staff. The auditor did not express an opinion on internal controls.
- Audit and contingencies: The auditor issued an unqualified opinion on the 2023 financial statements with a going-concern emphasis and identified acquired-intangible valuation and goodwill impairment as critical audit matters. The filing says a court ordered Studebaker to pay $550,000, but no payments had been received by the filing date; payments from a separate GSG settlement also had stopped after January 2023. The filing does not clearly state a collectible value for these claims.
- Other significant risks: The company cites Nasdaq listing and filing compliance, limited trading liquidity, potential dilution from securities, pharmaceutical licensing and regulatory exposure, supplier and inventory risks, cyber/privacy threats, and dependence on management. It states that it had not adopted a formal cybersecurity risk-management program.
Important facts for investors to verify
- Confirm the company’s identity and current corporate structure: the provided filing is for TRxADE HEALTH, Inc., despite the request naming Scienture Holdings, Inc.
- Review the final proceeds, adjustments and any earn-out conditions from the $22.5 million marketplace sale, and how sale proceeds were allocated, including the special dividend.
- Assess post-sale cash, debt maturities, receivables-funding obligations and the company’s ability to fund operations; year-end liquidity figures predate the major asset sale and dividend.
- Verify the status and terms of the proposed Lafayette Energy investment and any related-party approvals or subsequent changes.
- Review subsequent filings for discontinued operations, remaining revenue sources, remediation of material control weaknesses, Nasdaq compliance, and the status or collectability of disclosed legal claims.